Research Article
CSF-Targeted Proteomics Indicate Amyloid-Beta Ratios in Patients with Alzheimer’s Dementia Spectrum
Table 2
Demographics and clinical characteristics of the study population.
| | CN | MCI | AD | value |
| Number | 225 | 381 | 113 | | Age (years) | | | | <0.001 | Gender (F/M) | 126/99 | 173/208 | 45/68 | 0.007 | Education (years) | | | | 0.011 | Cognitive assessments | | | | | CDR | | | | <0.001 | ADAS-11 | | | | <0.001 | ADAS-13 | | | | <0.001 | MMSE | | | | <0.001 | Amyloid β | | | | | Aβ1-42 | | | | <0.001 | Aβ1-42/1-40 | | | | <0.001 | Aβ1-42/1-38 | | | | <0.001 | Targeted proteomics | | | | | IASNTQSR | | | | <0.001 | VAELEDEK | | | | <0.001 | VVSSIEQK | | | | <0.001 | GDSVVYGLR | | | | 0.001 | EPVAGDAVPGPK | | | | 0.004 | QETLPSK | | | | <0.001 |
|
|
CN: cognitively normal; MCI: mild cognitive impairment; AD: Alzheimer’s disease.
|